anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods and kits for treating or alleviating masseter muscle hypertrophy by local administration of a Clostridial derivative, such as a botulinum toxin, to the masseter muscle are described. Methods and kits for reducing lower face width and for reducing prominence of the masseter muscle of a human are also described.Methods and kits for treating or alleviating masseter muscle hypertrophy by local administration of a Clostridial derivative, such as a botulinum toxin, to the masseter muscle are described. Methods and kits for reducing lower face width and for reducing prominence of the masseter muscle of a human are also described. Disclosed are devices, systems and methods for remote safe driving. One exemplary method includes detecting an emergency situation, and in response to the detecting the emergency situation, switching operation of the vehicle to a low-power operation mode that comprises shutting down a subset of vehicular components, and periodically transmitting a location of the vehicle to a remote monitoring center. Another exemplary method includes selecting at least one of a set of vehicular driving actions, and transmitting, over a secure connection, the at least one of the set of vehicular driving actions to the vehicle, wherein the set of vehicular driving actions is generated based on a classification of driver behavior.
Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m\^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
Virus-specific CD4+T cell help and CD8+ cytotoxic T cell responses are critical for the maintenance of effective immunity in chronic viral infections. The importance of the CD4+T cells has been documented in HIV infection. A T1-specific CD4+T cell line from a healthy volunteer immunized with a canarypox vector expressing gpl20 has been developed. The cell line was restricted to DR13, which is common in the U.S. in both Caucasians and African-Americans and is one of the major haplotypes in Africans. Amino acid substitutions in the T1 epitope were made to induce a stronger epitope-specific CD4+T cell response than the original epitope resulting in an improved CD4 epitope. A polypeptide comprising the enhanced CD4 epitope can be used as a component in compositions either alone or in combination with other adjuvants and other immunogenic compositions to induce a more effective immune response to HIV infection.
??????               ABSTRACT OF THE DISCLOSURE     An improved method for lymphoscintigraphy or magnetic resonance lymphography involves subtraction of a negative image produced using a gross imaging agent from a positive image produced with a specific antibody imaging agent.  Another embodiment of the invention uses an antibody to lymphatic tissue as an imaging agent for lymphatics.  A further embodiment uses a magnetic resonance image enhancing agent for magnetic resonance lymphography.     Reagents and kits for use in the foregoing method are also provided.
INTRODUCTION: Fifty percent of pregnant females experience pain with 20% reporting long-term pain post-partum. Pregnant females undergo changes in foot anthropometry, lower extremity alignment, and joint laxity. It is unknown if asymmetric alterations may be related to development of pain. The purpose of this study was twofold: 1) to compare asymmetric alignment in pregnant females with and without pain during pregnancy and in nulliparous controls and 2) to assess the relationship between asymmetric alignment and pain severity in all participants.
METHODS: Ten pregnant females in their third trimester and nine nulliparous controls participated. Bilateral asymmetry of foot length, width, arch index, arch height index, arch rigidity index, arch drop, rearfoot angle, and pelvic obliquity were determined. Joint laxity and musculoskeletal pain were also assessed. ANOVAs were utilized to compare asymmetries between pregnant females reporting pain (n = 5), those not reporting pain (n = 5), and controls. Spearman's Rho correlations were used to relate asymmetry to pain magnitude (α = 0.05).
RESULTS: No statistical differences (p>0.05) were found between pregnant females with or without pain and controls for any of the metrics. Negative correlations were found between arch index asymmetry and low back pain (p = 0.005), foot length asymmetry and lower leg pain (p = 0.008), and pelvic obliquity and lower leg pain (p = 0.020). Positive correlations were found between foot width asymmetry and knee pain (p = 0.028), as well as arch drop asymmetry and upper leg (p = 0.024), knee (p = 0.005), and lower leg pain (p = 0.019).
CONCLUSIONS: This study was successful in identifying potential targets for prevention and treatment of pain in pregnancy. Furthermore, because pain during pregnancy may be predictive of pain post-partum, it is important to conduct future research to determine both if interventions such as footwear or exercise can prevent or treat these asymmetries and prevent post-partum pain.
Bupropion hydrochloride extended-release tablets (XL) are not approved for smoking cessation treatment; however, bupropion HCl sustained-release is approved for this use. Serious neuropsychiatric adverse events have been reported in patients taking bupropion for smoking cessation. These postmarketing reports have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide [see Adverse Reactions (6.2)].  Some patients who stopped smoking may have been experiencing symptoms of nicotine withdrawal, including depressed mood. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessation attempt without medication. However, some of these adverse events occurred in patients taking bupropion who continued to smoke. 

     Neuropsychiatric adverse events occurred in patients without and with pre-existing psychiatric disease; some patients experienced worsening of their psychiatric illnesses.
Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
PROBLEM TO BE SOLVED: To provide a center dispense suture package for e.g. avoiding the rock-up when the suture is pulled out from the package by trying some possible means such as providing a friction plate member related to the inner dispensing wall and a flange member on the base and pushing the bottom surface by a pushing means. SOLUTION: The suture package 5 has a tray 10 and the friction plate member 70. By the way, a flat base 20 has the top lane 21, the bottom plane 22 and the peripheral flange 24. Also as for the flat base 20, its outer wall upwardly extends from the top plane around the peripheral flange 24, and the inner dispensing wall 50 upwardly extends from the top plane. Moreover, the friction plate member 70 is a flat member with top plane 72, the bottom plane 74 and the peripheral flange 75 and has further a discharge opening for taking out suture and each rowed hole to the tray 10 and has a rock flange rim 80 on the peripheral flange 75. The rock flange rim 80 curves when the friction plate member 70 inserted in the tray 10 curves.
Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, poses a significant public health and economic burden. Although socioeconomic factors such as income and education have been implicated in AF incidence and outcomes, the potential sex-specific associations remained underexplored. This narrative review aimed to fill this gap by synthesizing existing literature on the sex-specific impact of socioeconomic factors on AF incidence, treatment, and outcome. Among these socioeconomic factors, we identified income and education as the most frequently cited determinants. Nevertheless, the magnitude and direction of these sex differences remained inconsistent across studies. The review uncovered that many studies did not include sex in the analysis when assessing the impact of socioeconomic factors on AF. We highlighted that there is a paucity of studies employing sex-stratified reporting and sex interaction analyses, thereby hindering a deeper understanding of these relationships.
The invention discloses a fluorescent probe for cyclooxygenase-2 in cancer cells by coupling celecoxib and a preparation method thereof, wherein the structure of the fluorescent probe compound is shown as a formula I. The probe is based on conjugation of a naphthamide to celecoxib using a flexible hexyl linker. Due to the PET process in solution, the probe is inhibited. When it binds to cyclooxygenase-2, the fluorescence intensity becomes stronger due to the release of the PET process. The advantage is that in the presence of cancer cells expressing high levels of COX-2, the probe exhibits strong single photon and two-photon fluorescence emissions due to selective binding of COX-2 inhibitors, and the probe is able to distinguish between cancer cells and normal cells. Experiments on tumor mice and organs show that the tumor site selective imaging and the targeted therapy are good.
The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
OBJECTIVE: Despite the suggested topiramate serum level of 5-20 mg/L, numerous institutions have observed substantial drug response at lower levels. We aim to investigate the correlation between topiramate serum levels, drug responsiveness, and adverse events to establish a more accurate and tailored therapeutic range.
METHODS: We retrospectively analyzed clinical data collected between January 2017 and January 2022 at Seoul National University Hospital. Drug responses to topiramate were categorized as "insufficient" or "sufficient" by reduction in seizure frequency ≥ 50%. A population pharmacokinetic model estimated serum levels from spot measurements. ROC curve analysis determined the optimal cutoff values.
RESULTS: A total of 389 epilepsy patients were reviewed having a mean dose of 178.4 ± 117.9 mg/day and the serum level, 3.9 ± 2.8 mg/L. Only 5.6% samples exhibited insufficient response, with a mean serum level of 3.6 ± 2.5 mg/L while 94.4% demonstrated sufficient response, with a mean 4.0 ± 2.8 mg/L, having no statistical significance. Among the 69 reported adverse events, logistic regression analysis identified a significant association between ataxia and serum concentration (p = 0.04), with an optimal cutoff value of 6.5 mg/L.
INTERPRETATION: This study proposed an optimal therapeutic concentration for topiramate based on patients' responsiveness to the drug and the incidence of adverse effects. We recommended serum levels below 6.5 mg/L to mitigate the risk of ataxia-related side effects while dose elevation was found unnecessary for suboptimal responders, as the drug's effectiveness plateaus at minimal doses.
Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
Autogenous grafts are currently considered the gold standard in regenerative and reconstructive procedures. However, these procedures require a second surgical site to provide the tissue graft. In autogenous gingival grafts, the area commonly selected for graft harvesting is the palate, which is linked to great discomfort and morbidity for the patient. In order to overcome these limitations, xenogeneic and alloplastic materials have been tested as tissue substitutes, but their results are still considerably inferior when compared to autogenous grafts. Faced with this superiority, another approach to favor the use of autogenous grafting is to develop materials that provide greater postoperative comfort and patient safety. Since the main complaint arising from the technique is related to pain resulting from the remaining surgical wound on the palate, it is interesting to look for mechanisms to reduce this sensitivity and accelerate the healing process. For this, the use of tilapia skin as a postoperative dressing seems to be a good alternative. Thus, the purpose of this study is to evaluate the use of tilapia skin, with the intention of accelerating the palate healing process, and to serve as a protector barrier during the healing process. Patients treated according to two techniques for palate protection after autogenous gingival graft harvesting will be evaluated: C- use of surgical cement and T- use of tilapia skin. Will be selected 60 patients of both sexes,\> 18 years old, requiring the removal of the palate graft for periodontal surgery. At the time of graft removal, palate thickness and graft dimensions will be measured. After 7, 14 and 30 days, the patient's discomfort and the difficulty in chewing and speaking will be recorded through a visual analog scale, the consumption of analgesic, and the dimensions of the surgical wound on the palate. For statistical analysis, two-way ANOVA will be performed and t-test paired on the obtained results.
Compositions and methods are provided for generating islet-like cell clusters. The methods include culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having Bone Morphogenetic Protein (BMP) activity (e.g., a BMP polypeptide). The effective amount of said molecule having BMP activity (e.g., BMP polypeptide) is sufficient to induce the formation of islet-like cell clusters. The methods further include treating or attenuating insulin-deficiency disorders, including type 1 diabetes. In one non-limiting embodiment, an insulin-deficiency disorder in a subject is treated or attenuated by culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having BMP activity (e.g., a BMP polypeptide) such that tho formation of islet-like cell clusters occurs. A therapeutically effective amount of the islet-like cell clusters which produce insulin are then transplanted into a subject in need to treat the insulin-deficiency disorder..
Achieving recommended treatment targets in management of hyponatremia is challenging: plasma sodium must be increased effectively but, at the same time, overcorrection has to be prevented. Yet, predictors of change of sodium over time have not been delineated properly. It was found, that evidence hinting to the fact that sodium baseline itself is crucial with respect to sodium evolution.

The goal of this study is to gather prospective data in order to precisely delineate the role of initial sodium levels by correlating those to plasma sodium evolution and electrolyte free water evolution. It is aimed to decipher patterns of sodium evolution with respect to anthropometric data, such as body composition analyses and blood pressure and markers of innate regulation mechanisms of body volume like aldosterone and renin. In addition, apart from these clinical aspects, a better appreciation of the physiological responses to hyponatremia treatment in terms of water and electrolyte balances is undoubtedly necessary to improve understanding of the body's mechanisms involved in osmotic homeostasis and cell volume control. Since studies to date also lack consideration of the intracellular department, the aim is to close that gap.
Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The limited literature and increasing interest in studies on cardiac electrophysiology, explicitly focusing on cardiac ion channelopathies and sudden cardiac death in diverse populations, has prompted a comprehensive examination of existing research. Our review specifically targets Hispanic/Latino and Indigenous populations, which are often underrepresented in healthcare studies. This review encompasses investigations into genetic variants, epidemiology, etiologies, and clinical risk factors associated with arrhythmias in these demographic groups. The review explores the Hispanic paradox, a phenomenon linking healthcare outcomes to socioeconomic factors within Hispanic communities in the United States. Furthermore, it discusses studies exemplifying this observation in the context of arrhythmias and ion channelopathies in Hispanic populations. Current research also sheds light on disparities in overall healthcare quality in Indigenous populations. The available yet limited literature underscores the pressing need for more extensive and comprehensive research on cardiac ion channelopathies in Hispanic/Latino and Indigenous populations. Specifically, additional studies are essential to fully characterize pathogenic genetic variants, identify population-specific risk factors, and address health disparities to enhance the detection, prevention, and management of arrhythmias and sudden cardiac death in these demographic groups.
A trollius chinensis phenol A and a preparation method and application thereof relate to a new substance with in-vitro anti-inflammatory effect and a method and application thereof. The invention provides a novel substance with in-vitro anti-inflammatory activity, and a preparation method and application thereof. Trolliol A has chemical name of 1- (3, 4-dihydroxyphenyl) -3-hydroxypropan-2-one and molecular formula of C  9  H  10  O  4  . The preparation method comprises the following steps: 1. extracting flos Trollii with 70% ethanol; 2. dispersing the ethanol recovered extract with water, and loading on D101 macroporous resin column; 3. separating the fraction eluted by D101 macroporous resin 30% ethanol by repeated silica gel column chromatography, and reusing the high-purity fractionThe preparation method of the compound comprises the steps of preparing a monomer compound by using a liquid chromatography, and identifying the monomer compound as a new compound by using a spectroscopy, and naming the new compound as trollius chinensis phenol A. The trollflower phenol A is used for preparing anti-inflammatory medicine. IC of the inhibition ratio of the trollius chinensis phenol A to the proinflammatory factors TNF-alpha and IL-1 beta released by mouse macrophage (RAW 264.7) stimulated by LPS  50  18.8 mu M and 14.6 mu M respectively, which shows that the anti-inflammatory agent has better anti-inflammatory activity in vitro. The invention belongs to the field of research on active ingredients of natural medicines.
The present disclosure relates to a process for controlling the crystal form of 3-pyridyl-1-hydroxy-ethylidene-1,1-bisphosphonic acid salt (Risedronate). The process employs a pH adjustment step to induce the proper hydrate form and thereby avoiding inadvertent nucleation of undesired hydrate forms. Particularly disclosed is a process for preparing 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid salt in the hemipentahydrate crystal form, said process comprising the steps of : (a) dissolving in an admixture of isopropyl alcohol and water, 3-pyridyl-l-hydroxy-ethylidene-1,1-bisphosphonic acid and an inorganic base in sufficient amount to provide a pH of 6, to form a solution; (b) heating the solution from about 50 Deg. C to about 60 Deg. C to form a heated solution; (c) filtering said heated solution to form a filtered solution; (d) adjusting the pH of said filtered solution with an inorganic acid to a pH range of from 4.7 to 5 while maintaining the temperature at the level obtained in step (b) to form a neutralized solution; (e) cooling the neutralized solution to a temperature of about 20 Deg. C to about 40 Deg. C to form a nucleating slurry of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid salt; (f) adding to said slurry isopropyl alcohol and sufficient inorganic acid to provide a pH of from 4.7 to 5.2 to form a ripened slurry of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid salt in the hemipentahydrate crystal form; and (g) isolating 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid salt hemipentahydrate.
The preparation of a cosmetic composition for conditioning colored products comprises injecting water using injectors into several enclosures containing different products to produce a solution of the composition, and selecting an expected level of property of the composition to control the injection of water. The enclosures optionally belong to a same refill, and are defined by even cartridge compartments. The water is simultaneously and sequentially injected into the enclosures under pressure, in which the temperature of the water is higher than 80[deg]C and the pressure is 10 bars. The preparation of a cosmetic composition for conditioning colored products, comprises injecting water using injectors into several enclosures containing different products to produce a solution of the composition, and selecting an expected level of property of the composition to control the injection of water. The enclosures optionally belong to a same refill, and are defined by even cartridge compartme nts. The water is simultaneously and sequentially injected into the enclosures under pressure, in which the temperature of the water is higher than 80[deg]C and the pressure is 10 bars. The enclosure is delimited by a wall to disperse the water under the pressure in which the enclosure having a keratin-coloring agent, and by a perforable wall. The quantity of the water injected into the enclosure is controlled by an electrical control element in which the water is injected under vapor and liquid phases. The injection of water in several enclosures is carried out to have a predefined volume of the cosmetic composition. The injectors are arranged to perforate the perforable wall. The selected property is related to a color/coloring capacity of the composition. The solutions are collected in a container, which contains a compound to be mixed with the solutions. Independent claims are also included for the following: (1) an extraction apparatus; and (2) a unit for the preparation of cosme tic composition.